

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

8449-156-999

APPLICATION NO

09/369,941

APPLICANT

Kensil C.

FILING DATE

August 6, 1999

GROUP

1632

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>mm</i>	D01	4,469,863	Ts'o et al.			
	D02	4,522,811	Eppstein et al.			
	D03	5,023,243	Tullis			
	D04	5,057,540	Kensil et al.			
	D05	5,273,965	Kensil et al.			
	D06	5,352,449	Beltz et al.			
	D07	5,443,829	Kensil et al.			
	D08	5,583,112	Kensil et al.			
	D09	5,650,398	Kensil et al.			
	D10	5,977,081	Marciani			
	D11	6,231,859	Kensil			
	D12	6,524,584	Kensil			
	D13	6,544,518	Friede et al.			
	D14	6,558,670	Friede et al.			
	D15	6,645,495	Kensil et al.			
	D16	2002/0164341	Davis et al.			
	D17	2003/0091599	Davis et al.			
	D18	2003/0224010	Davis et al.			
	D19	2003/0161834	Friede et al.			
<i>mm</i>	D20	09/760,506	Kensil et al.			01/12/01

## FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
<i>mm</i>	E01	WO 02/32450	4/25/02	PCT		
	E02	WO 98/37919	9/3/98	PCT		
	E03	WO 95/26204	10/5/95	PCT		
	E04	WO 98/40100	9/17/98	PCT		
	E05	BE 9908885	4/19/99	Belgium		
<i>mm</i>	E06	EP 1005368	3/10/98	Europe		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>mm</i>	F01	Agrawal et al., 1988, Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 85(19):7079-7083.
<i>mm</i>	F02	Agrawal S. 1992, Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10(5):152-158
<i>mm</i>	F03	Beaucage et al., 1981, Deoxynucleotide phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tet. Let. 22:1859-1862

7-27-04

F04	Boggs et al., 1997, Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 7(5):461-471
F05	Campbell & Peerbaye, 1992, Saponin. <i>Res. Immuno.</i> 143:526-530
F06	Carson et al., 1997, Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med.</i> 186(10):1621-1622
F07	Chavali & Campbell, 1987, Immunomodulatory Effects of Orally-Administered Saponins and Nonspecific Resistance Against Rabies Infection. <i>Int. Archs. Allergy Appl. Immun.</i> 84:129-134
F08	Chavali et al., 1988, Immunopotentiality by Orally-Administered <i>Quillaja</i> Saponins : Effects in Mice Vaccinated Intraperitoneally Against Rabies. <i>Clin. Exp. Immunol.</i> 74:339-343
F09	Chavali et al., 1987, An <i>In Vitro</i> Study of Immunomodulatory Effects of Some Saponins. <i>Int. J. Immunopharmac.</i> 9(6):675-683
F10	Dalsgaard, K. 1978, A study of the isolation and characterization of the saponin <i>quil a</i> . <i>Acta Veterinaria Scandinavica</i> 69:1-40
F11	Elkins et al., 1999, Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. <i>J Immunol.</i> 162(4):2291-2298
F12	Froehler B, 1986, Deoxynucleoside H-Phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues. <i>Tet. Let.</i> 27:5575
F13	Froehler et al., 1986, Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. <i>Nucleic Acids Res.</i> 14(13):5399-5407
F14	Gaffney et al., 1988, Large-scale oligonucleotide synthesis by the H-Phosphonate method. <i>Tet. Let.</i> 29:2619-2622
F15	Garegg et al., 1986, Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. <i>Tet. Let.</i> 27:4051-4054
F16	Garegg et al., 1986, Nucleoside H-phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. <i>Tet. Let.</i> 27:4055-4058
F17	Goodchild, J. 1990, Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. <i>Bioconjugate Chem.</i> 1:165
F18	Higuchi et al. Structure of desacylsaponins obtained from the bark of <i>quillaja saponaria</i> . <i>Phytochemistry</i> 26:229-235
F19	Kensil et al., 1992, Structure/Function relationship in adjuvants from <i>Quillaja saponaria</i> Molina. <i>Vaccine</i> 92 (Cold Spring Harbor Laboratory Press) pp. 35-40.
F20	Kim et al., 2001, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. <i>Vaccine.</i> 19(4-5):530-537
F21	Kirkby et al., Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. <i>Behav Pharmacol.</i> 1996 Nov;7(6):513-525.
F22	Klinman et al., 1996, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci U S A.</i> 93(7):2879-2883
F23	Krieg et al., 1996, Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev.</i> 6(2):133-139
F24	Krieg et al., 1998, CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge. <i>J Immunol.</i> 161(5):2428-2434
F25	Lipkin, 1995, "Vegemania: Scientists Tout the Heath Benefits of Saponins", <i>Science News</i> 148:392-393
F26	Maharaj et al., 1986, Immune Responses of Mice to Inactivated Rabies Vaccine Administered Orally: Potentiation by <i>Quillaja</i> Saponin. <i>Can. J. Microbiol.</i> 32:414-420
F27	Marciani et al., 1991, Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. <i>Vaccine.</i> 9(2):89-96
F28	Newman et al., 1992, Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. <i>J Immunol.</i> 148(8):2357-2362
F29	Rao & Sung, 1995, Saponins as Anticarcinogens. <i>J. Nutr.</i> 125:717S-724S,
F30	Uhlmann et al., Antisense oligonucleotides: A new therapeutic principle. <i>Chem. Rev.</i> 9:544-584

EXAMINER		DATE CONSIDERED	7-27-04
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			